|Bid||55.00 x 900|
|Ask||71.50 x 800|
|Day's Range||65.65 - 66.71|
|52 Week Range||60.23 - 118.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.93|
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.
Incyte Corporation (NASDAQ:INCY), a large-cap worth US$14.42b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...
WILMINGTON, Del.-- -- Directed by an Academy Award ® winning filmmaker in the documentary short subject category, “Something So Rare” chronicles the lives of four people living with MPNs, rare blood cancers MPN community encouraged to access new resources and participate in awareness initiatives in support of MPN Awareness Day Today on MPN Awareness Day and throughout September, Blood Cancer Awareness ...
WILMINGTON, Del.-- -- Study met primary and key secondary endpoints, demonstrating significant improvement from baseline in EASI score and reduced itch compared to vehicle Results presented at EADV support planned initiation of global, pivotal Phase 3 program Incyte Corporation today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ...
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
Incyte Corporation (INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with cholangiocarcinoma. The initial CDx, which will include detection of activating FGFR2 translocations, is expected to be incorporated into FoundationOne®CDx, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay and broad CDx platform. “There is an urgent need for a novel, biomarker-based, targeted therapeutic approach for patients with cholangiocarcinoma.
After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a moderation in momentum in the holiday-shortened ...
The following stocks are currently in the midst of strong trendsaccording to VantagePoint , an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action ...
Incyte Corporation (INCY) today announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement. Dave plans to remain at Incyte until the end of this year and will provide support during the transitional period. "Since joining Incyte in 2014, Dave has been an invaluable part of the leadership team.
Biotech stocks are hot and have rallied by 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB) since late May. The recent increase has helped the ETF rise by 14% for the year, beating the S&P 500's gain of 9%. Companies like Celgene Corp. ( CELG), Regeneron Pharmaceuticals Inc. ( REGN) and Incyte Corp. ( INCY) may rise by 10% or more in the coming weeks based on the technical charts, leading the charge higher. The Nasdaq Biotech ETF is breaking out as it rises above a long-term downtrend that has been in place since the summer of 2015.
Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018 compared to $1.54 billion in 2017. Incyte is expected to report net adjusted income of $245.1 million in 2018 compared to net adjusted income of -$313.1 million in 2017. Incyte’s stock price has fallen nearly 42.4% over the last 12 months and nearly 26.5% year-to-date in 2018.
Incyte’s (INCY) product portfolio includes the targeted therapies and immunotherapies for the treatment of oncology and non-oncology diseases.
Momelotinib once looked like a promising treatment for a bone marrow disorder, but after mixed results in late-stage clinical trials, Gilead shelved it. Now it's sold the drug to a Canadian company.
Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year) compared to $326.4 million in the second quarter of 2017.
Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.
Incyte Corporation (NASDAQ: INCY) took it on the chin in April, as the company announced that its Phase 3 study for an experimental combo with Merk & Co., Inc. (NYSE: MRK) had failed to reach its primary endpoint.